Melbourne healthtech startup Everlab has raised $15 million in a seed funding round led by global growth equity firm Left Lane Capital.
Everlab offers preventive care with diagnostics, AI and doctor oversight
Everlab is a digital health platform focused on proactive and personalised prevention. It works on a membership system where members receive year-round access to a suite of diagnostic tests.
These include whole-body MRIs, blood testing, DEXA scans, VO2 max, ECG, glucose monitoring, CT coronary angiograms, and food journal analysis.
Related Article Block Placeholder
Article ID: 317225
These services are paired with digital-first doctor consultations and AI-generated summaries, which the company says form the basis of a personalised prevention plan tailored to each member’s risk profile.
According to Everlab, its tiered membership model is designed to make high-quality preventive care more accessible.
The flagship protocol membership is priced at $2,999 per year, while a lower-cost tier is available at $1,199 annually.
CEO and co-founder Marc Hermann said the company is working to reduce pricing further by automating clinical workflows.
“We believe the realisation of equitable preventive health lies in intelligent automation,” he said. “Everlab is built to ensure world-class care is no longer limited by income or postcode,” Hermann told SmartCompany.
AI healthtech platform integrates with national medical systems
At the core of the platform is Everlab’s proprietary AI system, which the company says ingests and interprets structured and unstructured health data. This includes lab results, imaging, and specialist reports from a range of providers.
Rather than attempting to replace legacy healthcare infrastructure, Everlab has focused on interoperability, building integrations with national pathology and radiology systems.
“We took a more pragmatic and scalable approach, building on top of the existing systems rather than working around them,” Hermann said.
“This level of interoperability has been critical to ensuring clinical continuity and regulatory compliance.”
According to the company, the platform reduces the time required for a clinician to complete a comprehensive preventive health review from around 10 hours to under 10 minutes.
Everlab states that every diagnostic process is still overseen by a licensed doctor, who applies clinical judgement before any results are shared with a member.
“We’ve built an internal multidisciplinary team of researchers, clinicians, and engineers who work side by side to ensure that AI is applied safely, effectively, and in clinically meaningful ways,” ” Hermann said.
“While large language models (LLMs) are known to hallucinate, we’re mitigating that risk by heavily investing in training custom models and applying domain-specific constraints.
“Our expert clinicians validate every single result, apply their judgement, and ensure our AI-driven insights are grounded in real-world medical standards.”
Everlab is targeting early disease detection and biomarker insights
To date, Everlab says it has processed more than one million biomarkers. According to the company, around 2.5% of members have received test results that uncovered potentially serious conditions, such as gastrointestinal tumours, arterial blockages or early-stage cancers.
Related Article Block Placeholder
Article ID: 320220
A meta-analysis of members retested at the six-month mark found that over one-third of modifiable biomarkers had improved, the company said.
Hermann said the platform avoids broad or indiscriminate screening, instead tailoring tests to individual risk profiles.
“We’re not advocates of broad or indiscriminate screening. For example, we wouldn’t routinely order MRIs for healthy 18-year-olds. But when the context calls for early and thorough investigation, we act decisively,” he said.
Seed funding to accelerate growth and global expansion
Everlab reports a customer waitlist in the tens of thousands and says it is on track for 20x growth this year. In recent months, it has launched in multiple Australian cities, and the company plans to expand into international markets through 2026.
“Looking ahead, we plan to maintain our aggressive growth trajectory through 2026, including expansion into international markets,” Hermann said
In addition to the expansion of its clinical network, the fresh cash injection will help grow its engineering and medical teams and further develop its AI-powered infrastructure.
“For us, sustainable growth means not just meeting demand, but doing so with reputable systems, scalable infrastructure, and proven clinical outcomes across diverse populations,” Hermann said.
“We’re building the future of preventative healthcare. Even at seed level, we delivered the kind of impact and momentum that is more typical of a later-stage business.”